Glenmark settles patent litigation with Janssen Pharma

Trade

• Watchlist
• Portfolio
• Message
• Set Alert

 

 

Choose Stock Exchange: BSE LIVE NSE LIVE

26 Aug, 2025 12:21

Volume

Todays L/H

More

×

Moneycontrol Bureau

Pharma major Glenmark on Tuesday said its US generics arm has settled a litigation with Janssen Pharmaceuticals over patent actions concerning Norgestimate and Ethinyl Estradiol tablets in various strengths.

Glenmark's Norgestimate and Ethinyl Estradiol tablets are a generic version of Janssen's Ortho Tri-cyclen tablets, which are used as an oral contraceptive.

Under the terms of the settlement agreement, Glenmark will be able to market and distribute its copy drug under a royalty bearing license from Janssen on Dec 31, 2015, or earlier under certain circumstances, the company said.

Glenmark's sales and margins will get a boost given that there will be very little competition for the product, when it is launched in the US market. 

Janssen currently markets Ortho Tri-cyclen in the United States and total US sales for year ending June 2012 were about USD 397 million, Glenmark said, citing IMS Health data.

Glenmark shares were trading down 0.8 percent at Rs 434.25 on NSE in afternoon trade.

Also Read: May not see 35% growth in H1 sustaining in H2, says Glenmark